Effects of Tumor Necrosis Factor-alpha Inhibitors on the Incidence of Tuberculosis
![]() |
Park, Hyun Jin
(College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
Choi, Bo Yoon (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) Sohn, Minji (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) Han, Na Young (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) Kim, In-Wha (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) Oh, Jung Mi (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) |
1 | Golimumab. Micromedex Solutions. Truven Health Analytics, Inc. Greenwood Village, CO. Available from http://www.micromedexsolutions.com. Accessed Oct 30, 2018. |
2 | Etanercept. Micromedex Solutions. Truven Health Analytics, Inc. Greenwood Village, CO. Available from http://www.micromedexsolutions. com. Accessed Oct 30, 2018. |
3 | Kuek A, Hazleman BL, Ostor AJ. Immunemediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J 2007;83:251-60. DOI |
4 | Blandizzi C, Gionchetti P, Armuzzi A, et al. The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases. Int J Immunopathol Pharmacol 2014;27(Suppl):1-10. |
5 | Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British society for rheumatology biologics register. Arthritis Rheum 2006;54:2368-76. DOI |
6 | Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the research in active rheumatoid arthritis (ReAct) trial. Ann Rheum Dis 2007;66:732-9. DOI |
7 | Sampaio-Barros PD, van der Horst-Bruinsma IE. Adverse effects of TNF inhibitors in SpA: are they different from RA? Best Pract Res Clin Rheumatol 2014;28:747-63. DOI |
8 | Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoidarthritis associated with tumor necrosis factor antagonists inSweden. Arthritis Rheum 2005;52:1986-92. DOI |
9 | Ai JW, Zhang S, Ruan QL, et al. The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-a antagonist: a metaanalysis of both randomized controlled trials and registry/cohort studies. J Rheumatol 2015;42(12):2229-37. DOI |
10 | Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2016;14(10):1385-97.e10. DOI |
11 | Capogrosso Sansone A, Mantarro S, Tuccori M, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Saf 2015;38(10):869-88. DOI |
12 | Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008;214:149-60. DOI |
13 | Ruiz Garcia V, Burls A, Cabello JB, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev 2017;9:CD007649. DOI: 10.1002/14651858.CD007649.pub4. |
14 |
Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor- |
15 | Liao H, Zhong Z, Liu Z, et al. Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis 2017;20(2):161-8. DOI |
16 | Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf 2016;15(suppl):11-34. DOI |
17 | Singh JA, Nooribaloochi S, Singh G. Golimumab for theumatoid arthritis (Review). Cochrane Database Syst Rev 2010;1: CD008341. DOI: 10.1002/14651858.CD008341. |
18 | Firestein GS, Corr M. Common mechanisms in immune-mediated inflammatory disease. J Rheumatol Suppl 2005;73:8-13. |
19 | Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology 2014;53:1872-85. DOI |
20 | Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: a meta-analysis. Exp Ther Med 2016;12(3):1693-704. DOI |
21 |
Xie X, Chen J, Peng Y, et al. Meta analysis of infection risks of anti-TNF- |
22 | Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007;12(1):16-21. DOI |
23 | Xu Z, Xu P, Fan W, et al. Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med 2017;14(4):3491-500. DOI |
24 |
Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF- |
25 | Ke WM, Chen LS, Parng IM, et al. Risk of tuberculosis in rheumatoid arthritis patients on tumour necrosis factor-alpha inhibitor treatment in Taiwan. Int J Tuberc Lung Dis 2017;17(12):1590-95. DOI |
26 | Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health 2018;21(3):95-100. DOI |
27 | Green S, Higgins JPT, Alderson P, et al. Chapter 1: introduction. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration; 2011. Available from http://www.handbook.cochrane.org. Accessed Oct 30, 2018. |
28 | Pollock M, Fernandes RM, Becker LA, et al. What guidance is available for researchers conducting overviews of reviews of healthcare interventions? A scoping review and qualitative metasummary. Syst Rev 2016;5(1):190. DOI: 10.1186/s13643-016-0367-5. DOI |
29 | Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta-analyses, Cochrane handbook for systematic reviews of interventions version 5.0.0 (updated February 2008). The Cochrane Collaboration. Available from http://www.cochrane-handbook.org. Accessed Oct 30, 2018. |
30 | Wang Z. Converting odds ratio to relative risk in cohort studies with partial data information. J Stat Soft 2013;55(5)1-11. |
31 | Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993;73(3):431-45. DOI |
32 | Becker LA, Oxman AD. Chapter 22: overviews of reviews. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions (version 5.1.0). The Cochrane Collaboration; 2011. Available from http://www.handbook.cochrane.org. Accessed Oct 30, 2018. |
33 | Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206. DOI |
34 | Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008; 8(10):601-11. DOI |
35 | Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301(2):418-26. DOI |
36 | Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNFalpha and activates immune effector functions. Cytokine 1995; 7(3):251-9. DOI |
37 | Bonovas S, Pantavou K, Evripidou D, et al. Safety of biological therapies in ulcerative colitis: an umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol 2018;32-33:43-7. DOI |
38 | Adalimumab. Micromedex Solutions. Truven Health Analytics, Inc. Greenwood Village, CO. Available from http://www.micromedexsolutions. com. Accessed Oct 30, 2018. |
39 | Infliximab. Micromedex Solutions. Truven Health Analytics, Inc. Greenwood Village, CO. Available from http://www.micromedexsolutions.com. Accessed Oct 30, 2018. |
40 | Certolizumab pegol. Micromedex Solutions. Truven Health Analytics, Inc. Greenwood Village, CO. Available from http://www.micromedexsolutions.com. Accessed Oct 30, 2018. |
![]() |